"We are very pleased to announce the expansion of our agreement with DiscoveRx, which grants GE Healthcare exclusive global distribution rights to HitHunter cAMP assays and provides our customers with more options for cutting edge, high throughput screening technology. We are already known for our SPA screening products; adding the DiscoveRx portfolio allows us to offer a more comprehensive suite of screening technologies to our customers, combined with the high quality and service they have come to expect," says Ger Brophy, general manager of Discovery Sciences, at GE Healthcare.
The agreement not only grants GE Healthcare global exclusivity for DiscoveRx's cAMP assays, it also expands distribution of the company's portfolio of kinase assays, with exclusive distribution in the Asia Pacific region.
HitHunter cAMP assays are homogeneous, non-radioactive, cell-based assays used to screen for G-protein coupled receptor (GPCR) activation in a microplate-based format. GPCRs represent a large class of membrane proteins that play an important role in cell signaling pathways and are important targets for drug discovery.
"DiscoveRx's HitHunter GPCR and kinase products are well accepted by drug discovery customers. We are tremendously excited about this important step forward, which broadens the global access of our HitHunter products through a premier supplier of life science research tools," says Pyare Khanna, Ph.D., CEO of DiscoveRx Corp.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases, and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $15 billion unit of General Electric Company (NYSE:GE - News). Worldwide, GE Healthcare employs more than 43,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
About DiscoveRx
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. DiscoveRx pioneered the use of beta-galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, kinases and other major drug target classes. DiscoveRx HitHunter products have been adopted in pharmaceutical and biotech drug screening initiatives for a number of years. For more information, visit www.discoverx.com
Contact: GE Healthcare, Americas Kristin Silady, 732-457-8149 kristin.silady@ge.com
Source: GE Healthcare
